Gene editing takes a major step toward ending daily cholesterol pills

Photo caption: The Scribe Therapeutics’ STX-1150 treatment could replace or significantly reduce reliance on taking daily statins (such as simvastatin) to lower LDL cholesterol. Photo credit: Oregon State University via Flickr. CC BY-SA 2.0.Article by Bronwyn Thompson. New Atlas – January 25, 2026. Source: Scribe Therapeutics.

A new CRISPR-based one-off procedure that lowers “bad” cholesterol is expected to enter Phase I human trial in 2026. If successful, it could be the first approved genetic-silencing method on the market, replacing the need for long-term medication and slashing the risk of cardiovascular disease. […]

Click here to view original web page at www.newatlas.com